HSDT (Helius Medical Technologies Inc.) Company Projected Revenue
The projected sales volume of Helius Medical (HSDT) correlates with the recognition of the PoNS system as a rehabilitation standard and insurance coverage. The level of 0.01 represents the current value of this metric. A monopoly status in non-invasive therapy allows Helius Medical (HSDT) to flexibly manage its pricing power. High user loyalty is sustained by treatment efficacy, although growth rates are constrained by bureaucratic complexities regarding regulatory payments.
Analytical breakdowns and data insights for company Helius Medical Technologies Inc. (HSDT)
- current price and projected stock value:
- business market valuation indicators:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Helius Medical|HSDT - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Helius Medical|HSDT - Company Total Debt|Debts to Book Capitalization Helius Medical|HSDT - Company Long-Term Debts|Company Short-Term Debt Helius Medical Technologies|Quick Ratio heliusmedical.com
- earnings and market ratios statistics:
HSDT - Final Profit|Expected Profit Helius Medical|HSDT - Business Payback Period|Forward P/E Multiple Helius Medical|HSDT - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Helius Medical|HSDT - Company profit before taxes, interest and amortization|Earnings per share for the last twelve months Helius Medical Technologies|HSDT - Earnings per share for the last 12 months|Quarterly EPS earnings growth heliusmedical.com|HSDT - Earnings per share growth rate in current year|Expected earnings per share growth for next year Helius Medical
- sales and revenue data:
Fundamental company analysis:Helius Medical Technologies
For Helius Medical (HSDT), this indicator serves as a filter for the operational viability of the business within the neurostimulation segment. Analysis of the company's future sales figures is based on commercial flow forecasts, allowing for an assessment of revenue stability between quarterly reports. Growth in this metric confirms market demand, while a decline signals systemic risks. Outsourcing device assembly minimizes capital expenditures, enhancing the significance of this indicator. The trend line determines the long-term investment attractiveness of the asset.
Analysis of competing companies
Company Future Sales Volume BIIB (Biogen Inc.)|NBIX (neurocrine.com) - Company Future Revenue|Company Projected Revenue Regencell Bioscience Holdings Limited RGC|AXSM - Company Future Sales Volume|ACADIA Pharmaceuticals Inc - Projected Sales Volume|Company Expected Sales Volume Xenon Corp|VKTX: Projected Sales Volume|Company Revenue Forecast SUPN|CPRX (Catalyst Pharmaceuticals, Inc.) - Projected Sales Volume|Denali (DNLI) - Company Future Sales|Projected Sales Volume HRMY|Company Future Sales Volume Biohaven Corp BHVN|Projected Sales Volume AMLX (Amylyx Pharmaceuticals)|Projected Sales Volume trevitherapeutics.com TRVI|PRAX - Company Projected Revenue|AVXL: Company Projected Revenue|CBLL: Projected Sales Volume|Prothena Corp - Company Future Revenue|Company Projected Revenue Alector Inc.|annexonbio.com (ANNX) - Company Future Sales|Projected Sales Volume OMER|Neurogene Inc - Company Revenue Forecast|AC Immune Corp - Company Future Sales Volume|Company Projected Revenue Volume VYGR (Voyager Corp)|NMRA - Company Projected Revenue|SCLX (scilexholding.com) - Company Revenue Forecast|TVGN: Projected Sales Volume|Company Expected Sales Volume Alpha Cognition Inc. (ACOG)|Company Future Sales Volume CGTX|Projected Sales Volume Inhibikase Pharma|Company Projected Revenue Cassava Sciences, Inc. (SAVA)|ASRT (assertiotx.com) - Company Future Revenue|Company Projected Revenue Coya Therapeutics COYA|VistaGen Therapeutics, Inc. (VTGN) - Company Expected Sales Volume|Ovid Rx - Projected Sales Volume|Company Future Revenue ABOS (Acumen Pharmaceuticals, Inc)|CRVO: Projected Sales Volume|Company Expected Sales Volume Alterity Therapeutics Limited (ATHE)|Company Projected Revenue Clene Inc|Company Projected Revenue PEPG|Projected Sales Volume JUNS|Company Future Sales Relmada Corp|Annovis Bio, Inc. - Company Future Sales Volume|Projected Sales Volume Grace Therapeutics Inc GRCE|AIFF - Company Projected Revenue|Company Future Sales Klotho Neurosciences Inc KLTO|NRSN (neurosense-tx.com) - Company Future Sales Volume|Reviva Pharmaceuticals, Inc. - Company Future Revenue|Company Projected Revenue MetaVia Inc.|Company Future Sales Volume neuraxis.com (NRXS)|Projected Sales Volume PASG|NEUP - Company Expected Sales Volume|Projected Sales Volume NERV (Minerva Neurosciences Corp)|ATHA: Company Revenue Forecast|Addex Therapeutics - Projected Sales Volume|Company Future Sales Alzamend Neuro, Inc. ALZN|CYCN: Projected Sales Volume|Company Future Sales Volume Protagenic Therapeutics, Inc.|KTTA (Pasithea Therapeutics Corp) - Projected Sales Volume|Projected Sales Volume Cortigent Medical|Company Projected Revenue Avenue Therapeutics (ATXI)|Company Projected Revenue BCLI (brainstorm-cell.com)|Projected Sales Volume CARA (Cara Therapeutics)|Company Future Revenue CHRO|ELYM - Company Projected Revenue|Company Future Sales Intra-Cellular Therapies ITCI|LBPH: Projected Sales Volume|Company Revenue Forecast MRNS|Company Future Sales Volume NKGN|NRBO (NeuroBo Pharmaceuticals Inc) - Company Projected Revenue Volume|Company Projected Revenue Sage Therapeutics, Inc (SAGE)|Synaptogenix, Inc - Company Revenue Forecast|Projected Sales Volume TRVN (Trevena, Inc.)|Vigil Neuroscience Inc. (VIGL) - Company Expected Sales Volume|WENA: Company Future Sales Volume|CERE - Projected Sales Volume
